New animal study shows promise for development of Parkinson's disease drug

June 9, 2011, IOS Press

Few treatments for Parkinson's disease (PD) restore function for extended periods. In a new study published today in the inaugural issue issue of the Journal of Parkinson's Disease, an international group of researchers report that platelet-derived growth factor-BB (PDGF-BB) restored function in rodents and shows promise as a clinical candidate drug for treatment of PD.

Parkinson's disease is the second most common , affecting 1% of the population over the age of 65. It is characterized by loss of (neurons) from the mid-brain which use the to help control voluntary movements. Investigators from NeuroNova AB, Stockholm, Sweden, the Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden, The Parkinson's Institute, Sunnyvale, CA, USA, and Motac Neuroscience Ltd, Manchester, UK, found that behavioral, tissue and in experimental models of Parkinson's disease in rodents could be counteracted by infusion of PDGF-BB. This could offer an alternative strategy to restore function in PD.

"In animal models of nigrostriatal injury, a two weeks treatment with platelet-derived growth factor-BB resulted in long-lasting restoration of striatal dopamine transporter binding sites and expression of nigral tyrosine hydroxylase," commented Anders Haegerstrand, MD, PhD, Chief Scientific Officer, NeuroNova AB, Stockholm, Sweden."It also normalized amphetamine-induced rotational behavior in 6-hydroxydopamine lesioned rats. Platelet-derived growth factor-BB promoted proliferation of in the subventricular zone. The effects on dopaminergic neurons and functional recovery could be blocked by co-infusion with a proliferation inhibitor, indicating a link between the proliferative and anti-parkinsonian effects. Based on the current data, we consider platelet-derived growth factor-BB a clinical candidate drug for treatment of Parkinson's disease."

More information: The article is "Restorative Effects of Platelet Derived Growth Factor-BB in Rodent Models of Parkinson's Disease" by Olof Zachrisson, Ming Zhao, Annica Andersson, Karin Dannaeus, Johan Häggblad, Ruben Isacson, Elisabet Nielsen, Cesare Patrone, Harriet Rönnholm, Lilian Wikstrom, Kristofer Delfani, Alison L. McCormack, Theo Palmer, Donato A. Di Monte, Michael P. Hill, Ann Marie Janson Lang, and Anders Haegerstrand. Journal of Parkinson's Disease. 1(1). DOI 10.3233/JPD-2011-0003

Related Stories

Recommended for you

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Flu may be spread just by breathing, new study shows; coughing and sneezing not required

January 18, 2018
It is easier to spread the influenza virus (flu) than previously thought, according to a new University of Maryland-led study released today. People commonly believe that they can catch the flu by exposure to droplets from ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.